Your browser doesn't support javascript.
loading
Predictive Factors of Stent Patency in Iliofemoral Venous Diseases in a Multicentre Cohort Study.
Espitia, Olivier; Douane, Frédéric; Hersant, Jeanne; Abbadie, Fabrice; Sobocinski, Jonathan; Heautot, Jean-François; Miossec, Annaïg; Lapébie, François-Xavier; Hartung, Olivier.
Afiliação
  • Espitia O; Nantes Université, CHU Nantes, Department of Internal and Vascular Medicine, Nantes, France. Electronic address: olivier.espitia@chu-nantes.fr.
  • Douane F; Nantes Université, CHU Nantes, Department of Radiology, Nantes, France.
  • Hersant J; Department of Vascular Medicine, CHU Angers, France.
  • Abbadie F; Department of Vascular Medicine, CH Vichy, France.
  • Sobocinski J; Department of Vascular Surgery, CHU Lille, France.
  • Heautot JF; Department of Radiology, CHU Rennes, France.
  • Miossec A; Nantes Université, CHU Nantes, Department of Internal and Vascular Medicine, Nantes, France.
  • Lapébie FX; Department of Vascular Medicine, CHU Toulouse, France.
  • Hartung O; Department of Vascular Surgery, CHU Nord, Marseille, France.
Eur J Vasc Endovasc Surg ; 65(4): 564-572, 2023 04.
Article em En | MEDLINE | ID: mdl-36642400
ABSTRACT

OBJECTIVE:

This study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), and post-thrombotic syndrome (PTS).

METHODS:

Consecutive patients from January 2014 to December 2020 with history of LL vein stenting from seven hospitals were included. All patients received an iliac or common femoral venous stent and had at least a six month follow up available with stent imaging. Anticoagulant and antiplatelet therapy strategies employed after venous stenting are reported and compared between groups.

RESULTS:

This study included 377 patients 134 NIVL, 55 aDVT, and 188 PTS. Primary patency was statistically significantly higher in the NIVL group (99.3%) compared with the PTS group (68.6%) (p < .001) and the aDVT group (83.6%) (p = .002). PTS patients received a statistically significantly greater number of stents (p < .001) and had more stents below the inguinal ligament (p < .001). Median follow up was 28.8 months (IQR 16, 47). Discontinuation of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT, and 95.7% for the PTS group (p < .001). Discontinuation of anticoagulation therapy at the last assessment was 93.2% for NIVL, 25.0% for aDVT, and 70.3% for the PTS group (p < .001). The only predictor of worse primary patency in the aDVT group was long term anticoagulation before stenting.

CONCLUSION:

Patients with NIVL have better primary patency after venous stenting than patients with venous thrombotic disorders. Long term anticoagulation before stenting was the only factor associated with poorer primary patency in patients with aDVT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombose Venosa / Síndrome Pós-Trombótica Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombose Venosa / Síndrome Pós-Trombótica Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article